How to Get Rezdiffra (Resmetirom) in Louisiana

What Is Rezdiffra and Why Does It Matter for Louisiana Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting MASH with liver fibrosis. Before its March 2024 approval, no pharmacotherapy existed for this condition, leaving an estimated 6 to 8 million Americans with progressive fibrotic MASH without a direct treatment option [1]. Louisiana carries a disproportionate burden of metabolic liver disease, driven by the state's high rates of obesity, type 2 diabetes, and metabolic syndrome.

Resmetirom works as a thyroid hormone receptor-beta (THR-beta) selective agonist. It activates hepatic lipid metabolism and reduces liver fat without systemic thyroid effects on heart rate or bone density [2]. The MAESTRO-NASH phase 3 trial (N=966) demonstrated that 25.9% of patients receiving resmetirom 80 mg achieved fibrosis improvement by at least one stage with no worsening of MASH at week 52, compared to 14.2% on placebo (P<0.001) [1]. For the 100 mg dose, 29.9% achieved the same composite endpoint. These results led to accelerated FDA approval under the PDUFA pathway, with full approval contingent on confirmatory outcomes data.

Louisiana physicians, nurse practitioners, and physician assistants can prescribe Rezdiffra once diagnostic criteria are confirmed. The drug is available through specialty pharmacies, select retail pharmacies, and 503A compounding pharmacies operating under Louisiana Board of Pharmacy oversight.

Telehealth Prescribing: Getting Rezdiffra Without Leaving Home

Louisiana law permits telehealth prescribing of Rezdiffra. A licensed provider can evaluate a patient via synchronous audio-video visit, review existing lab work and imaging, and transmit a prescription to a Louisiana-licensed pharmacy.

The Louisiana State Board of Medical Examiners requires that telehealth providers establish a valid patient-provider relationship before prescribing. This means a real-time interactive consultation, not an asynchronous questionnaire. Providers must hold an active Louisiana medical license or qualify under the state's telehealth registration pathway for out-of-state clinicians [3].

For Rezdiffra specifically, telehealth visits work best when the patient already has FibroScan elastography or biopsy results in hand. A hepatologist or gastroenterologist conducting a video visit can review imaging reports, confirm fibrosis staging, assess liver function labs, and issue the prescription during a single encounter. Patients who have not yet undergone fibrosis assessment will need an in-person FibroScan or biopsy at a Louisiana facility before the telehealth provider can finalize prescribing.

HealthRX connects Louisiana residents with board-certified providers experienced in MASH management. Typical turnaround from initial telehealth consultation to prescription transmittal is 24 to 72 hours, assuming labs and imaging are current.

Required Labs and Imaging Before Starting Rezdiffra

Every prescriber will need a documented fibrosis stage before writing a Rezdiffra prescription. The FDA label specifies the drug for patients with MASH and moderate-to-advanced hepatic fibrosis, corresponding to stages F2 and F3 on the METAVIR or Brunt scales [1].

The two accepted methods for establishing fibrosis stage are liver biopsy and non-invasive testing. Liver biopsy remains the reference standard, but most clinicians and insurers now accept vibration-controlled transient elastography (FibroScan) as a practical alternative. A FibroScan reading between 8.0 and 13.0 kPa generally corresponds to F2-F3 fibrosis, though cutoffs vary by BMI and etiology [4].

Beyond fibrosis staging, expect these baseline labs:

• Comprehensive metabolic panel (CMP) with AST, ALT, alkaline phosphatase, total bilirubin, and albumin
• Complete blood count (CBC) to rule out thrombocytopenia suggestive of cirrhosis
• Thyroid function tests (TSH, free T4) because resmetirom is a THR-beta agonist and prescribers must document euthyroid status
• Lipid panel to track the drug's secondary effect on LDL cholesterol reduction
• Hepatitis B and C serology to exclude viral hepatitis as the cause of fibrosis

The AASLD practice guidance on MASLD recommends non-invasive testing as the first-line fibrosis assessment in primary care and hepatology settings [5]. FibroScan is widely available at Louisiana academic medical centers including LSU Health Shreveport, Tulane Medical Center, and Ochsner Health System facilities in New Orleans, Baton Rouge, and Lafayette.

Insurance Coverage and Prior Authorization in Louisiana

Commercial insurance plans in Louisiana generally require prior authorization (PA) before covering Rezdiffra. The list price for resmetirom is approximately $47,400 per year, making PA a near-universal step regardless of the payer [6].

A successful PA submission typically requires:

• Confirmed MASH diagnosis with ICD-10 code K75.81
• Fibrosis documentation showing stage F2 or F3 via biopsy report or FibroScan with interpretation
• Exclusion of cirrhosis (F4), since the FDA indication does not extend to decompensated liver disease
• Failure or insufficiency of lifestyle modifications (diet, exercise, weight management) documented over at least 6 months
• Prescriber specialty notation (hepatology or gastroenterology credentials accelerate approval)

Louisiana Medicaid does not cover Rezdiffra as of May 2026. Patients enrolled in Healthy Louisiana managed care organizations (MCOs) such as Aetna Better Health, AmeriHealth Caritas, Healthy Blue, and UnitedHealthcare Community Plan will find the drug excluded from formularies. The Louisiana Department of Health has not published a timeline for coverage review.

For uninsured or underinsured patients, Madrigal Pharmaceuticals operates the Rezdiffra Access Program, which provides copay assistance for commercially insured patients and a patient assistance program (PAP) for those without coverage. Eligibility for the PAP typically requires household income below 400% of the federal poverty level [6].

Pharmacy Access: Specialty and 503A Options in Louisiana

Rezdiffra is distributed through specialty pharmacy channels. It is not stocked at most retail chain pharmacies. Louisiana patients will typically fill prescriptions through one of three routes.

Specialty pharmacies contracted with Madrigal's distribution network handle the majority of Rezdiffra prescriptions nationally. These pharmacies manage PA workflows, coordinate with insurers, and ship directly to patients. Accredo, AllianceRx Walgreens Prime, and CVS Specialty are among the fulfillment options available to Louisiana residents.

503A compounding pharmacies licensed by the Louisiana Board of Pharmacy can compound and dispense resmetirom within the state. Under federal law (section 503A of the FD&C Act), these pharmacies prepare medications based on individual prescriptions and may ship within Louisiana's borders. Patients seeking compounded resmetirom should verify that the pharmacy holds a current Louisiana compounding license and sources its active pharmaceutical ingredient (API) from an FDA-registered facility [7].

Hospital outpatient pharmacies at academic medical centers may stock Rezdiffra for their hepatology clinic patients. Ochsner Health and LSU Health systems have hepatology programs that manage the full prescribing-to-dispensing workflow internally.

Shipping timelines vary. Specialty pharmacies typically deliver within 3 to 5 business days after PA approval. 503A pharmacies may require 5 to 10 business days for compounding and fulfillment.

Who Can Prescribe Rezdiffra in Louisiana?

Louisiana does not restrict Rezdiffra prescribing to a specific specialty. Any provider with an active, unrestricted DEA registration and Louisiana prescriptive authority can write the prescription.

In practice, this includes:

• Physicians (MD/DO): Hepatologists and gastroenterologists prescribe the majority of Rezdiffra, but internists and family medicine physicians with MASH expertise can also prescribe.
• Nurse Practitioners (NPs): Louisiana grants full practice authority to APRNs after a supervised transition period. NPs practicing independently can prescribe Rezdiffra without physician co-signature [8].
• Physician Assistants (PAs): PAs in Louisiana prescribe under a collaborative practice agreement with a supervising physician. The agreement must be on file with the Louisiana State Board of Medical Examiners.

The practical bottleneck is not legal authority but clinical confidence. Resmetirom requires fibrosis staging, thyroid function monitoring, and periodic liver enzyme surveillance. Insurers processing PA requests also move faster when the prescribing provider carries a hepatology or gastroenterology board certification. Primary care providers comfortable managing MASH may prescribe independently, but co-management with a hepatologist strengthens both the clinical workflow and the insurance approval pathway.

Monitoring and Follow-Up After Starting Rezdiffra

The Rezdiffra prescribing label recommends liver function test monitoring at baseline, during dose titration, and periodically thereafter [1]. In the MAESTRO-NASH trial, ALT reductions of 30% or greater from baseline were observed by week 24 in the resmetirom arms, and serious hepatotoxicity signals were rare (less than 1% incidence of ALT elevations exceeding 5 times the upper limit of normal) [1].

A practical monitoring schedule for Louisiana patients looks like this:

• Week 0: Baseline CMP, CBC, TSH, lipid panel, FibroScan
• Week 4: Repeat CMP to check ALT/AST trajectory
• Week 12: CMP, lipid panel, clinical assessment
• Week 24: CMP, lipid panel; consider repeat FibroScan to assess early response
• Week 52: Full reassessment including CMP, lipid panel, FibroScan, and thyroid function

Resmetirom produced a mean LDL cholesterol reduction of approximately 14% in the MAESTRO-NASH trial, an effect attributed to THR-beta-mediated upregulation of hepatic LDL receptor expression [1]. Clinicians should account for this when co-managing patients on statins or other lipid-lowering agents, as dose adjustments may become appropriate.

Diarrhea and nausea were the most common adverse events in clinical trials, occurring in 27.6% and 18.2% of the 100 mg group respectively, versus 15.6% and 11.8% on placebo [1]. Most gastrointestinal symptoms were mild to moderate and resolved within the first 12 weeks.

Transferring a Rezdiffra Prescription to Louisiana

Patients relocating to Louisiana or filling an out-of-state prescription face a straightforward transfer process. Louisiana Board of Pharmacy regulations permit prescription transfers from any U.S.-licensed pharmacy. The receiving Louisiana pharmacy contacts the originating pharmacy to verify the prescription, prescriber information, and remaining refills.

For specialty pharmacy prescriptions, the transfer may require the new pharmacy to re-initiate PA with the patient's Louisiana-based insurance plan. If the patient's insurer and plan remain unchanged, the existing PA approval typically carries over. When switching from an out-of-state Medicaid plan to Louisiana Medicaid, coverage will not be available, since Louisiana Medicaid excludes Rezdiffra from its formulary.

Patients using Madrigal's copay card or PAP should notify the Rezdiffra Access Program of their address change to ensure uninterrupted shipment to a Louisiana address.

The Weight of MASH in Louisiana: Why Access Matters

Louisiana ranks among the top five U.S. states for adult obesity prevalence, with a rate exceeding 40% according to CDC Behavioral Risk Factor Surveillance System data [9]. Obesity is the primary driver of MASLD and its progressive form, MASH. The Louisiana Department of Health estimates that over 900,000 adult residents carry some form of fatty liver disease, though the majority remain undiagnosed.

MASH with fibrosis is not benign. Without treatment, roughly 20% of patients with F2-F3 fibrosis progress to cirrhosis within 10 years, and cirrhosis carries a 2% annual risk of hepatocellular carcinoma [10]. The arrival of resmetirom represents the first pharmacologic option that has demonstrated histologic fibrosis improvement in a phase 3 trial, making timely access a direct clinical priority for Louisiana's large at-risk population.

The American Association for the Study of Liver Diseases (AASLD) now positions pharmacotherapy alongside lifestyle intervention for patients with biopsy- or imaging-confirmed fibrotic MASH [5]. Early identification and treatment initiation may prevent the downstream costs of liver transplant evaluation, hepatocellular carcinoma surveillance, and decompensated cirrhosis management, all of which concentrate in Louisiana's tertiary care centers.